Literature DB >> 17169791

Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader community.

Lauren E Abrey1, Katherine S Panageas.   

Abstract

Despite recent advances in the management of primary central nervous system lymphoma (PCNSL), recent population-based studies suggest that prognosis in the broader community has not improved substantially over the last 20 years. It is possible that this difference in outcome reflects a significant selection bias in the clinical series and trials reported. However, there is also preliminary evidence suggesting that patients in the community may not receive optimal management. There are many possible reasons that might account for disparities in care and outcome, but these have not been specifically addressed with regard to PCNSL. We have sought to elaborate some potential causes of these disparities; however, future studies are needed to identify and address specific barriers to care in the community.

Entities:  

Mesh:

Year:  2006        PMID: 17169791     DOI: 10.1080/10428190600881272

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma.

Authors:  Thomas S Uldrick; Sharon Pipkin; Susan Scheer; Nancy A Hessol
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

2.  Survival among patients with primary central nervous system lymphoma, 1973-2004.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen; Elizabeth B Claus
Journal:  J Neurooncol       Date:  2010-06-17       Impact factor: 4.130

3.  CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.

Authors:  Nadia N Laack; Brian Patrick O'Neill; Karla V Ballman; Judith Rich O'Fallon; Xiomara W Carrero; Paul J Kurtin; Bernd W Scheithauer; Paul D Brown; Thomas M Habermann; Joseph P Colgan; Mark R Gilbert; Roland B Hawkins; Roscoe F Morton; Harry E Windschitl; Tom R Fitch; Eduardo R Pajon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.